Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Sofosbuvir/velpatasvir/voxilaprevir is approved for 12-week use in patients with compensated cirrhosis who either have genotype 1-6 HCV infection and were previously treated with an NS5A inhibitor–containing regimen or have genotype 1a or 3 HCV infection and were previously treated with sofosbuvir[FDA Sofosbuvir Velpatasvir Voxilaprevir]
  • High SVR12 rates observed in phase III trials in patients with compensated cirrhosis and previous DAA experience
    • POLARIS-1: SVR12 93% in patients with cirrhosis, genotype 1-6 HCV infection, and previous NS5A inhibitor experience[Bourlière 2017]

Action required